Keith Gorden
About
Keith Gorden is a scholar working on Immunology, Infectious Diseases and Molecular Biology.
According to data from OpenAlex, Keith Gorden has authored 28 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 9 papers in Infectious Diseases and 9 papers in Molecular Biology. Recurrent topics in Keith Gorden's work include Antifungal resistance and susceptibility (9 papers), Peptidase Inhibition and Analysis (7 papers) and Immunotherapy and Immune Responses (6 papers). Keith Gorden is often cited by papers focused on Antifungal resistance and susceptibility (9 papers), Peptidase Inhibition and Analysis (7 papers) and Immunotherapy and Immune Responses (6 papers). Keith Gorden collaborates with scholars based in United States, United Kingdom and Germany. Keith Gorden's co-authors include John P. Vasilakos, Mark A. Tomai, Xiaohong Qiu, Sheila J. Gibson, Ross M. Kedl, Şefik Ş. Alkan, William C. Kieper, Kevin Gorski, Richard L. Miller and Patricia Fitzgerald‐Bocarsly and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.
In The Last Decade
Keith Gorden
28 papers receiving 1.3k citations
Hit Papers
Peers
Keith Gorden
Kiyotoshi Mori Japan
Ryutaro Fukui Japan
Jamie L. Brady Australia
Natasha Whibley United States
Giorgio Trinchieri United States
Lele Zhu United States
M. Lamine Mbow United States
Yasunobu Miyake Japan
Archana Monie United States
Soo-Hyun Chung Japan
Citations per year, relative to Keith Gorden Keith Gorden (= 1×)
peers
Kiyotoshi Mori
Countries citing papers authored by Keith Gorden
Since
Specialization
Citations
This map shows the geographic impact of Keith Gorden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Gorden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Gorden more than expected).
Fields of papers citing papers by Keith Gorden
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Keith Gorden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Gorden. The network helps show where Keith Gorden may publish in the future.
Co-authorship network of co-authors of Keith Gorden
This figure shows the co-authorship network connecting the top 25 collaborators of Keith Gorden. A scholar is included among the top collaborators of Keith Gorden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Gorden. Keith Gorden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chan, Anissa, Xiaohong Qiu, Mark Uhlik, et al.. (2022). Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies. Frontiers in Oncology. 12. 869078–869078.
2.
Bose, Nandita, Gautam Jha, Michele Gargano, et al.. (2020). Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. Anticancer Research. 40(3). 1467–1473.
3.
Bose, Nandita, Xiaohong Qiu, Mark Uhlik, et al.. (2019). Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers. The Journal of Immunology. 202(10). 2945–2956.
4.
Uhlik, Mark, Keith Gorden, Steven Leonardo, et al.. (2018). Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients. Cancer Research. 78(13_Supplement). LB–129.
5.
Thomas, Michael, Parvis Sadjadian, Jens Kollmeier, et al.. (2017). A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer. Investigational New Drugs. 35(3). 345–358.
6.
Bose, Nandita, Mark Matson, Xiaohong Qiu, et al.. (2017). Effect of imprime PGG on innate immune-activating pharmacodynamic changes in a phase I clinical study in healthy human volunteers.. Journal of Clinical Oncology. 35(7_suppl). 33–33.
7.
Bose, Nandita, Keith Gorden, Anissa Chan, et al.. (2017). Abstract B29: Innate immune modulation: The novel immunotherapeutic Imprime PGG triggers the anti-cancer immunity cycle in concert with tumor-targeting, anti-angiogenic and checkpoint inhibitor antibodies. Cancer Immunology Research. 5(3_Supplement). B29–B29.
8.
Chan, Anissa, Xiaohong Qiu, Richard M. Walsh, et al.. (2016). Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. PLoS ONE. 11(11). e0165909–e0165909.
9.
Bose, Nandita, Benjamin R. Harrison, Anthony W.H. Chan, et al.. (2016). Anti-beta glucan antibodies represent a mechanism-based biomarker to select patients responsive to the novel immunotherapeutic, Imprime PGG. European Journal of Cancer. 69. S106–S107.
10.
Leonardo, Steven, et al.. (2016). Abstract A160: Imprime PGG binds to neutrophils through complement, Fc, and dectin-1 receptors, priming these cells for enhanced ROS production and tumor cell cytotoxicity. Cancer Immunology Research. 4(1_Supplement). A160–A160.
11.
Fulton, Ross B., Steven Leonardo, Kathryn Fraser, et al.. (2016). Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy. Cancer Research. 76(14_Supplement). LB–89.
12.
Leonardo, Steven, et al.. (2015). Abstract 5034: Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity. Cancer Research. 75(15_Supplement). 5034–5034.
13.
Bose, Nandita, Mary A. Antonysamy, Myra L. Patchen, et al.. (2014). Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology. 32(15_suppl). 3045–3045.
14.
Leonardo, Steven & Keith Gorden. (2014). Enhancement of neutrophil signaling and effector function by Imprime PGG in response to tumor cells in biomarker positive individuals (TUM7P.937). The Journal of Immunology. 192(Supplement_1). 203.19–203.19.
15.
Bose, Nandita, Anissa Chan, Xiaohong Qiu, et al.. (2013). Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent. Frontiers in Immunology. 4. 230–230.
16.
Gorski, Kevin, William C. Kieper, Keith Gorden, et al.. (2006). Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. International Immunology. 18(7). 1115–1126.
17.
Gorden, Keith, Kevin Gorski, Sheila J. Gibson, et al.. (2005). Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8. The Journal of Immunology. 174(3). 1259–1268.
18.
Boyer, Michael W., Daniel A. Vallera, Patricia A. Taylor, et al.. (1997). The Role of B7 Costimulation by Murine Acute Myeloid Leukemia in the Generation and Function of a CD8+ T-Cell Line With Potent In Vivo Graft-Versus-Leukemia Properties. Blood. 89(9). 3477–3485.
19.
Gorden, Keith, et al.. (1993). Retroviral-mediated transfer of the murine interleukin-3 gene engineered for intracellular retention results in a myeloproliferative syndrome but is associated with circulating interleukin-3 levels.. PubMed. 21(9). 1245–54.
20.
Stueland, C S, Keith Gorden, & D C LaPorte. (1988). The isocitrate dehydrogenase phosphorylation cycle. Identification of the primary rate-limiting step.. Journal of Biological Chemistry. 263(36). 19475–19479.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kiyotoshi Mori Breakdown of academic impact, for papers by Ryutaro Fukui Breakdown of academic impact, for papers by Jamie L. Brady Breakdown of academic impact, for papers by Natasha Whibley Breakdown of academic impact, for papers by Giorgio Trinchieri Breakdown of academic impact, for papers by Lele Zhu Breakdown of academic impact, for papers by M. Lamine Mbow Breakdown of academic impact, for papers by Yasunobu Miyake Breakdown of academic impact, for papers by Archana Monie Breakdown of academic impact, for papers by Soo-Hyun Chung